ルー・ゲーリック病（筋萎縮性側索硬化症）

Lou Gehrig Disease Report - Is there a link between Lipitor and ALS?

発行	Visiongain
出版日	2007年08月	商品コード	57014
ページ情報	英文
価格	こちらの商品の販売は終了いたしました。

概要
原文目次
関連レポート

当商品の販売は、2011年08月12日を持ちまして終了しました。

原文目次

Abstract

Amyotrophic lateral sclerosis (ALS) also known as Lou Gehrig' s disease in the US, Maladie de Charcot in France and Motor Neuron Disease (MND) in the UK is a progressive neuromuscular disease characterised by the progressive degeneration of motor nerve cell in the brain (upper motor neurons) and spinal cord (lower motor). To date there is no cure for ALS. Present day medical management of the disease through the combinatorial use of medications and advancements in state-of-art technological devices for nutrition and breathing, have markedly increased the survival rate of ALS sufferers.

An article in SpokesmanReview states their may be a link between statins and ALS, with suggestions that Lipitor has triggered it in certain cases. The article sites the WHO as pointing out that high numbers have developed Lou Gehrig disease while on statins and advises doctors to discontinue therapy if patients develop ' serious neuromuscular disease such as ALS like symptoms' . Could Lipitor (still the biggest selling drug) actually cause ALS while the company itself thinks it will aid in the treatment of MS?

The report examines key ALS/ Lou Gehrig markets such as:

US
Japan
Germany
France
Italy
Spain
UK

Sanofi-Aventis' Rilutek (riluzole) is the only prescription drug currently approved for the treatment of ALS. Rilutek generated global revenue of over $153 million in 2006. Visiongain reveals that, Rilutek' s market value will continue to expand with, global revenues anticipated to exceed, $129 million 2007 in the seven major markets across the globe. What will it be in 2012? This report tells you.

Visiongain' s ALS Market Analysis & Forecasts, delves into Rilutek' s monopoly over the market in recent years, it present market share and trends envisaged in the medium future. This current report presents a three hundred and sixty degree examination of how present changes in Governmental Pharmaceutical Policies will impact on Rilutek as the main treatment for ALS in the seven major markets. Plus we examine how current and new drug treatments can take hold of the market, plus which companies will succeed in each market.

The report provides in-depth market analysis upon these areas, and extensively identifies the challenges faced by new market entrants, and what exciting market opportunities exist in this therapeutic area.

Why You Must Buy This Report? This report features tables, graphs and charts, news, insights, the past and present developments in ALS research. This report, will provide you with the complete understanding of the market indications for ALS, the institutions heralding ALS research, companies on the outlook to join in decoding, such matters as- directions to meeting primary unmet needs in ALS. When you buy this report, you have also bought, why big players in the biopharmaceutical business are filling their portfolios niche medical devices and diagnostics technologies products through major M&A.

With unmet medical needs this is this market set to grow with an ageing population and by how much? This report will tell you. Brought together in one easy to read, easily digested format, this report will keep you fully informed and up-to-date on the global ALS pharmaceutical market.

Why You Must Buy This Report: This report features tables, graphs and charts, news, insights, the past and present developments in ALS research. This report, will provide you with the complete understanding of the market indications for ALS, the institutions heralding ALS research, companies on the outlook to join in decoding, such matters as- directions to meeting primary unmet needs in ALS. When you buy this report, you have also bought, why big players in the biopharmaceutical business are filling their portfolios niche medical devices and diagnostics technologies products through major M&A.

Key questions that this report answers are:

What research over the past 20 years has failed? And why
What R&D opportunities exist for ' new comers' ?
Which current or future therapies will drive the ALS market?
The key companies involved in the market and their analysis?
What companies are joining in ALS research?
What treatment besides Rilutek, can improve ALS survival rate?
Which of the major markets has the highest prevalence?
What is the present state of the disease awareness?
Who are market leaders in medical devices M&A activities?
Which emerging markets are forcing big pharma into M&A deals?

Unique benefits to you when you order this report:

You can access your report whichever country you are in without using harddrive space
Primary research throughout. You will not find this information anywhere else
Report stored in your reading room for ever
Full searchable report when you buy the company or corporate editions
Copies can be printed off for offline reading
Packed with charts, analysis, figures, graphs and tables

Executive Summary

Chart 1. Rilutek Revenues Split between Seven Major Markets and Remaining Regions in 2006
Chart 2. Rilutek Revenues ($m) by Country in the Seven Major Markets
Chart 3. Overall Forecast for Rilutek in Seven Major Markets ($m),2007-2012
Table 1. Overall Forecast for Rilutek in Seven Major Markets ($m),2007-2012

1. Amyotrophic Lateral Sclerosis

1.1 Introducing Amyotrophic Lateral Sclerosis
1.2 The Progression of ALS
1.3 Risk Factors of ALS
1.4 The Diagnosis of ALS
1.5 The Demographic Impact of ALS
- Chart 4. Percentage distribution of ALS

Chapter 2. Treatment of ALS

2.1 What are the Treatment Options for ALS?
- 2.1.2 Rilutek (riluzole)
- 2.1.3Symptom Management with other Pharmacological Agents
- 2.1.4 Neurontin (Gabapentin)
  - Chart 5. Teva (Neurontin) Revenue Forecast,2007-2012
  - Chart 6. Pfizers (Neurontin) Revenue Forecast,2007-2012
  - Chart 7. Actavis (Neurontin) Revenue Forecast, 2007-2012
  - Chart 8. Apotex (Neurontin) Revenue Forecast,2007-2012
  - Chart 9. Pharmascience (Neurontin) Revenue Forecast, 2007-2012
- 2.1.5 Topamax (Topiramate)
  - Chart 10. Topamax Revenue 2003-2006

Chapter 3. Medical Devices used in ALS

3.1 Medical Devices and Future care in ALS
- 3.1.2 Air-way clearing Assistive Devices Technology
  - Table 2. Airway Clearance Medical Devices,Used during ALS patient care
- 3.1.3 Cost of Medical Devices in ALS
- 3.1.4 Will use of devices affect market growth?
- 3.1.5 Significant Mergers and Acquisition of Me dical Device Technologies
  - Table 3. M&A Medical Device and Technology Deals,2006

Chapter 4. Research into ALS treatments

4.1 Investor Focus on ALS Research
- 4.1.1 Potential candidates for ALS
- 4.1.2 The Antibiotic Minocycline may have a Role in ALS Treatment
- 4.1.3 Cox-2 (Nimesulide)
- 4.1.4 The Role of Apoptosis in ALS
- 4.1.5 Biological Markers for ALS
- 4.1.6 Gene Research in ALS
- 4.1.7 Gene Therapy
- 4.1.8 Gene Therapy Delivery Vehicle

Chapter 5. Future developments

5.1 Creatine Monohydrate
5.3 Xaliproden Hydrochloride to Regenerate NF
- Table 4. Failed Drugs and Present ALS Clinical Trials Pipeline

Chapter 6. Rilutek Regional Markets Analysis

6.1 US Market Outlook
- Chart 11. US Market Growth Rate 2002-2003
- 6.1.2 Market Share Dominated by US
  - Chart 12. US Health Budget Allocation in comparison to Other Regions
  - Chart 13. Population With and Without Health Insurance Coverage in the US
  - Chart 14. Split of Health Insurance Providers in the US
- 6.1.3 US Expenditure on Pharmaceutical products
  - Chart.15 US Pharmaceutical Market Revenue 2005-2006
- 6.1.4 US Rilutek Market Analysis
- 6.1.5 Rilutek Market Share
  - Chart.16 Rilutek Revenue 2005-2006
  - Chart 17. US Combined Rilutek Revenues 2003-2006
  - Chart 18. US Rilutek Revenue 2003-2006
- 6.1.6 Rising Medicare Part D to Affect Rilutek
- 6.1.7 US Dominates ALS Research
- 6.1.8 US Rilutek Revenue Forecast 2007-2012
  - Chart 19. US Rilutek Revenue Forecast 2007-2012
- 6.1.9 Drivers and Restraints of the US Rilutek Market
- 6.1.10 Drivers
- 6.1.11 Restraints
6.2 Japan Market Outlook
- Chart 20. Japan Pharmaceutical Revenues ($bn) 2004-2006
- 6.2.2 Japan' s Healthcare System
- 6.2.3 Medical Expenditure in Japan
  - Chart 21. Japan Medical Expenditure 1990s (JPY Trillions)
- 6.2.4 Japan Healthcare Strategic Reform
- 6.2.5 Strategic long-term care insurance care reforms
- 6.2.6 Japan Pharmaceutical Market Analysis
- 6.2.7 Rilutek Market Performance and Analysis
  - Chart 22. Japan Rilutek Combined Revenue 2003-2006
  - Chart 23. Japan Rilutek Revenue 2003-2006 in the two market sectors
  - Chart 24. Japan Rilutek Revenue Forecast 2007-2012
- 6.2.8 Drivers and Restraints
- 6.2.9 Drivers
- 6.2.10 Restraints
6.3 France Pharmaceutical Market Outlook
- Chart 25. France' s Pharmaceutical Market Revenues ($bn) 2002-2006
  - 6.3.1 Healthcare System
  - 6.3.2 France Health and Medical Expenditure
  - 6.3.3 Rilutek Market Performance and Analysis
    - Chart 26. Rilutek Combined Revenue in France,2003-2006
    - Chart 27. Rilutek Retail and Hospital Revenues in France, 2003-2006
    - Chart 28. France Rilutek Revenue Forecast,2007-2012
  - 6.3.4 Rilutek Market Drivers and Restraints
    - 6.3.4.1 Market Drivers
    - 6.3.4.2 Market Restraints
6.4 Germany Pharmaceutical Outlook
- Chart 29. Germany' s Pharmaceutical Revenues ($bn), 2002-2006
- 6.4.1 Germany Healthcare System
- 6.4.2 Pharmaceutical Sector Reforms
- 6.4.3 Germany Rilutek Market Performance and Analysis
  - Chart 30. Germany Rilutek Combined Revenues,2003-2006
  - Chart 31. Germany Rilutek Retail and Hospital Revenues,2003-2006
  - Chart 32. Germany Rilutek Retail Revenues by company in 2006
  - Chart 33. Germany Rilutek Hospital Revenues by company in 2006
  - Chart 34. Germany Rilutek Revenue Forecast, 2007-2012
- 6.4.4 Rilutek Market Drivers and Restraints
- 6.4.5 Market Drivers
- 6.4.6 Market Restraints
6.5 Italy Pharmaceutical Outlook
- Chart 33. Italy' s Pharmaceutical Revenues ($bn), 2004-2006
- 6.5.1 Italy' s Healthcare System and Reforms
- 6.5.2 Italy Rilutek Market Performance and Analysis
- 6.5.3 Prevalence of ALS in Italy
  - Chart 34. Italy' s Rilutek Revenues ($m), 2004-2006
- 6.5.4 Italy Rilutek Revenue Forecast,2007-2012
  - Chart 35. Italy Rilutek Revenue Forecast,2007-2012
- 6.5.5 Rilutek Market Drivers and Restraints
- 6.5.6 Market Drivers
- 6.5.7 Market Restraints
6.6 UK Pharmaceutical Outlook
- Chart 36. UK Global Pharmaceutical Revenues ($b),2002-2006
- 6.6.1 UK Healthcare system
- 6.6.2 UK NHS and Department of Health
- 6.6.3 NHS and Private Healthcare
- 6.6.4 UK Healthcare Insurance Policies
- 6.6.5 Current NHS Prescription Volumes
- 6.6.7 Dominance of Generic Market
- 6.6.8 UK Rilutek Market Performance and Analysis
  - Chart 37. UK Rilutek Combined Revenues ($m), 2003-2006
  - Chart 38. UK Rilutek Split Revenues ($m), 2003-2006
  - Chart 39. UK Rilutek Revenues Forecast,2007-2012
- 6.6.9 Rilutek Market Drivers and Restraints
- 6.6.10 Market Drivers
- 6.6.11 Market Restraints
6.7 Spain Pharmaceutical Outlook
- Chart 40. Spain Pharmaceutical Revenues ($bn), 2002-2006
- 6.7.1 Spain' s Rilutek Market Performance Analysis
  - Chart 41. Spain' s Combined Riluitek Revenues ($m), 2003-2006
  - Chart 42. Spain' s Riluitek Revenue Forecast,2006-2012
6.7. Rilutek Market Drivers and Restraints
- 6.7.1 Market Drivers
- 6.7.2 Market Restraints